Description

3-Quinolinecarboxylic Acid, 8-Bromo-1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7-(1-Piperazinyl)- is a high-purity advanced pharmaceutical intermediate (API intermediate) with a complex heterocyclic structure. This compound is of critical importance for its role as a key building block in the synthesis of modern fluoroquinolone antibiotics. It is primarily required by pharmaceutical R&D laboratories and manufacturing facilities engaged in the production of novel antibacterial agents.

Application

• Pharmaceutical Intermediate: Serves as a crucial precursor in the synthesis of next-generation fluoroquinolone antibiotic active pharmaceutical ingredients (APIs).
• Antibacterial Drug Research: Used in medicinal chemistry for the research and development of new antibacterial compounds with improved efficacy and spectrum of activity.
• Process Chemistry & Scale-Up: Employed in process optimization and pilot-scale production runs for antibiotic manufacturing.
• Reference Standard: Can be utilized as a high-purity analytical reference standard for quality control and method development in pharmaceutical analysis.
• Chemical Synthesis: Acts as a specialized building block for constructing complex quinoline-based molecular architectures in organic synthesis.

Basic Information

Item	Details
Product Name	3-Quinolinecarboxylic Acid, 8-Bromo-1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7-(1-Piperazinyl)-
CAS No.	109347-94-6
Molecular Formula	C17H17BrFN3O3
Molecular Weight	410.24 g/mol
Synonyms	8-Bromo-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(piperazin-1-yl)quinoline-3-carboxylic acid; 7-(1-Piperazinyl)-8-bromo-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid; 8-Bromo-1-cyclopropyl-6-fluoro-7-piperazin-1-yl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Intermediate for Fluoroquinolone Antibiotics; Bromo-cyclopropyl-fluoro-quinolinecarboxylic acid piperazinyl derivative
EINECS	Contact for details

Quality Control

Our 3-Quinolinecarboxylic Acid derivative is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, to ensure it meets the exacting standards required for pharmaceutical synthesis. A comprehensive Certificate of Analysis (COA) detailing purity, assay, and impurity profiles is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at controlled room temperature (typically 15-25°C). The compound may be hygroscopic; keep the container tightly sealed in a dry environment to prevent moisture absorption.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.